Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia
Phase 2
Recruiting
- Conditions
- Hyperalgesia
- Registration Number
- NCT03066739
- Lead Sponsor
- University of California, Irvine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 105
Inclusion Criteria
Inclusion Criteria:<br><br> - Subjects who provide written informed consent.<br><br> - Age 18 years old or older (no upper age limit for inclusion)<br><br> - Gender: male or female.<br><br> - Surgery: Posterior spinal fusions<br><br>Exclusion Criteria:<br><br> - Allergy to opiates<br><br> - Chronic pain other than the primary indication for surgery<br><br> - Psychiatric illness<br><br> - History of substance abuse problem including alcohol &/or cannabis<br><br> - BMI > 35<br><br> - Subjects under 18 years of age.<br><br> - Subject without the capacity to give written informed consent. 8. Female subjects<br> who are pregnant
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Occurrence of Opioid-induced hyperalgesia (OIH);Occurrence of Opioid-induced hyperalgesia (OIH)
- Secondary Outcome Measures
Name Time Method Opioid consumption;Opioid consumption;Cold Pressure Test;Cold Pressure Test;Visual Analog Scale (VAS) Pain scores;McGill short form questionnaire;Brief Pain Inventory